For postmenopausal cases having high anatomical stage (e.g., stage III), positive ER, negative HER2 breast cancer, voters agreed by 97% that for patients having ≥10 infiltrated lymph nodes (with very high stages), regardless of biomarkers (95%), even with recurrence score <25 (88%) to give combined chemotherapy and endocrine therapy. The gene discussed is ERBB2; the disease is breast carcinoma.